10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Georgia	31-0621189
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

900 Circle 75 Parkway, Suite 690, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered Symbol(s)
Common Shares without par value	SSY	NYSE American
Preferred Share Purchase Rights

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (of for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

The number of Common Shares, without par value, outstanding as of May 14, 2024 was 7,040,603.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

	March 31,
	2024			June 30,
	(unaudited)			2023
ASSETS
Current Assets:
Cash and cash equivalents	$	1,211		$	4,486
Receivables - net		3,078			2,592
Inventory		1,561			1,628
Current assets held for sale		3,512			1,920
Prepaid expense and other assets		1,604			1,648
Total current assets		10,966			12,274
Property, plant and equipment, at cost		12,302			11,259
Less accumulated depreciation		(9,399	)		(8,542	)
Property, plant and equipment - net		2,903			2,717
Noncurrent Assets:
Intangible asset		1,180			1,180
Noncurrent assets held for sale		0			5,812
Right of use assets		592			798
Other noncurrent assets		503			487
Total noncurrent assets		2,275			8,277
TOTAL ASSETS	$	16,144		$	23,268
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	1,532		$	1,067
Accrued payroll and related taxes		857			1,027
Current liabilities held for sale		563			1,326
Current operating lease liabilities		332			334
Other accrued expenses		675			1,115
Total current liabilities		3,959			4,869
Long-Term Liabilities
Noncurrent liability for professional liability risks		231			138
Long-term operating lease liabilities		273			481
Noncurrent liabilities held for sale		0			192
Other noncurrent liabilities		73			171
Total long-term liabilities		577			982
Commitments and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 7,041 shares at March 31, 2024 and 7,032 at June 30, 2023		3,521			3,516
Additional paid-in capital		10,747			10,746
Retained earnings (deficit)		(2,810	)		3,005
Accumulated other comprehensive income		150			150
Total Shareholders’ Equity		11,608			17,417
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	16,144		$	23,268

See notes to condensed consolidated financial statements.

2

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Net revenues	$	7,462		$	8,181		$	24,527		$	26,270
Costs and Expenses:
Cost of goods sold		4,339			4,755			13,871			13,642
Salaries, wages and benefits		2,652			2,543			7,937			7,547
Supplies		36			39			109			104
Purchased services		265			302			832			788
Other operating expenses		589			601			2,279			1,854
Rent and lease expense		92			92			275			276
Depreciation and amortization		342			316			960			873
Operating Profit (Loss)		(853	)		(467	)		(1,736	)		1,186
Other Income (Expense):
Gains on sale of assets		0			0			2			13
Interest income (expense), net		19			8			70			13
Earnings (Loss) from Continuing Operations before income taxes		(834	)		(459	)		(1,664	)		1,212
Income Tax Benefit		(10	)		(6	)		(5	)		(7	)
Earnings (Loss) from Continuing Operations		(824	)		(453	)		(1,659	)		1,219
Loss from Discontinued Operations, net of tax		(572	)		(309	)		(4,156	)		(1,588	)
Net Loss		(1,396	)		(762	)		(5,815	)		(369	)
Other comprehensive income		0			0			0			0
Comprehensive Loss	$	(1,396	)	$	(762	)	$	(5,815	)	$	(369	)
Loss Per Share:
Continuing Operations:
Basic	$	(0.12	)	$	(0.06	)	$	(0.24	)	$	0.17
Diluted	$	(0.12	)	$	(0.06	)	$	(0.24	)	$	0.17
Discontinued Operations:
Basic	$	(0.08	)	$	(0.04	)	$	(0.59	)	$	(0.23	)
Diluted	$	(0.08	)	$	(0.04	)	$	(0.59	)	$	(0.23	)
Net Loss:
Basic	$	(0.20	)	$	(0.11	)	$	(0.83	)	$	(0.05	)
Diluted	$	(0.20	)	$	(0.11	)	$	(0.83	)	$	(0.05	)
Weighted-Average Common Shares Outstanding:
Basic		7,041			7,032			7,038			7,015
Diluted		7,041			7,032			7,038			7,018

See notes to condensed consolidated financial statements.

3

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands)

(Unaudited)

	Common Shares				Additional Paid-in Capital		Retained Earnings (Loss)			Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity
	Shares		Amount
JUNE 30, 2023		7,032	$	3,516	$	10,746	$	3,005		$	150	$	17,417
Share options exercised		9		5		1		0			0		6
Net loss		0		0		0		(1,344	)		0		(1,344	)
SEPTEMBER 30, 2023		7,041		3,521		10,747		1,661			150		16,079
Net loss		0		0		0		(3,075	)		0		(3,075	)
DECEMBER 31, 2023		7,041		3,521		10,747		(1,414	)		150		13,004
Net loss		0		0		0		(1,396	)		0		(1,396	)
MARCH 31, 2024		7,041	$	3,521	$	10,747	$	(2,810	)	$	150	$	11,608
JUNE 30, 2022		6,954	$	3,478	$	10,736	$	4,800		$	106	$	19,120
Share options exercised		78		38		10		0			0		48
Net loss		0		0		0		(1,558	)		0		(1,558	)
SEPTEMBER 30, 2022		7,032		3,516		10,746		3,242			106		17,610
Net earnings		0		0		0		1,951			0		1,951
DECEMBER 31, 2022		7,032		3,516		10,746		5,193			106		19,561
Net loss		0		0		0		(762	)		0		(762	)
MARCH 31, 2023		7,032	$	3,516	$	10,746	$	4,431		$	106	$	18,799

See notes to condensed consolidated financial statements.

4

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months
	March 31,
	2024			2023
Net Cash Used in Operating Activities	$	(2,592	)	$	(119	)
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations		(1,089	)		(969	)
Expenditures for property, plant and equipment - discontinued operations		(91	)		(556	)
Proceeds from sale of property, plant and equipment - continuing operations		5			213
Proceeds from sale of Trace hospital operations - discontinued operations		500			0
Net Cash Used in Investing Activities		(675	)		(1,312	)
Cash Flows Provided by (Used in) Financing Activities:
Proceeds from share options exercises		6			49
Payments on long-term debt - discontinued operations		(14	)		(30	)
Net Cash Provided by (Used in) Financing Activities		(8	)		19
Net Decrease in Cash and Cash Equivalents		(3,275	)		(1,412	)
Cash and Cash Equivalents Beginning of Period		4,486			6,794
Cash and Cash Equivalents End of Period	$	1,211		$	5,382
Supplemental Disclosure of Cash Flow Information:
Cash Paid (Received) for:
Interest	$	(70	)	$	(46	)
Income taxes	$	105		$	(32	)
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	$	18		$	24

See notes to condensed consolidated financial statements.

5

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED MARCH 31, 2024

(all dollar amounts in thousands except per share amounts)

(Unaudited)

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2024 and for the three and nine month periods ended March 31, 2024 and 2023 have been prepared in accordance with Rule 8-03 and Article 8-03 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2023 balance sheet included in this interim filing has been derived from the audited consolidated financial statements at that date but does not include all the information and related notes required by GAAP for complete consolidated financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the SEC on September 28, 2023. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2024 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Throughout these notes to the condensed consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that SunLink Health Systems, Inc. or any particular subsidiary of the Company owns or operates any particular asset, business or property. Each operation and business described in this filing is owned and operated by a distinct and indirect subsidiary of SunLink Health Systems, Inc.

Note 2. – Business Operations

The Company’s continuing operations are composed of a pharmacy business and an information technology (“IT”) business.

The pharmacy business, is composed of four operational areas conducted in three locations in southwest Louisiana:

· Retail pharmacy products and services, consisting of retail pharmacy sales.

· Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.

· Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes.

· Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.

A subsidiary, SunLink Health Systems Technology (“SHST Technology”), provides information technology (“IT”) services to outside customers and to SunLink subsidiaries. The Company also owns a subsidiary which owns approximately twenty-five (25) acres of unimproved land in Ellijay, Georgia.

Series C Redeemable Preferred Shares

On August 2, 2023, the Board of SunLink declared a non-cash dividend per Common Share of one fractional interest in one of the Corporation’s Series C Redeemable Preferred Shares (the “Series C Preferred Shares” and each such

6

fraction of a Series C Preferred Share, a “Series C Fractional Interest”). Each of the 7,032 Series C Preferred Shares issued was entitled to one million (1,000,000) votes and each Series C Fractional Interest in a Series C Preferred Share was entitled to one thousand (1,000) votes out of such one million votes. Series C Fractional Interests could not be transferred separately from the Common Shares and were represented by the Common Shares. A further description of the Series C Preferred Shares and the Series C Fractional Interests and the terms and provisions thereof is set forth in the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2023. Each Common Share was entitled to one (1) vote as a Common Share and also one thousand (1,000) votes for the corresponding Series C Fractional Interest thereon, on each matter properly brought before a special shareholders’ meeting which was held on October 19, 2023 and at which the Corporation was reincorporated from the state of Ohio to Georgia (the “Special Meeting”). The Series C Fractional Interests were automatically redeemed and the Series C Preferred Shares cancelled.

COVID-19 Pandemic and CARES Act Funding

The Company continued to experience adverse after-effects of the COVID-19 pandemic in the quarter ended March 31, 2024 and believes such effects will likely continue to affect its assets and operations in the foreseeable future, particularly salaries and wages pressure, workforce shortages, supply chain disruption and broad inflationary pressures. Our ability to make estimates of any such continuing effects from current or evolving strains of COVID-19 on future revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is limited, depending, as they do, on the severity and length thereof; as well as any further government actions and/or regulatory changes intended to address such effects.

Note 3. – Discontinued Operations

All of the businesses discussed below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Sale of Trace Regional Hospital, medical office building and three patient clinics, Trace Extended Care operations –On January 22, 2024, the Company's indirect subsidiary, Southern Health Corporation of Houston, Inc. (“Southern”), reached a revised agreement for the sale of Trace Regional Hospital, a medical office building and three (3) patient clinics in Chickasaw County, MS, (collectively “Trace”) to Progressive Health of Houston, LLC (“Progressive”). Pursuant to those agreements, Southern sold certain personal and intangible property of Trace Regional Hospital and associated clinics to Progressive on January 22, 2024 for $500 pursuant to an asset purchase agreement ('Trace Assets Sale"), entered into a six-month net lease of certain hospital real property for $20 per month, and engaged Progressive under a management agreement to manage the operations of Trace pending receipt of certain regulatory approvals, which was received February 29, 2024. As a result of the transaction, Southern’s previous agreement with Progressive dated November 10, 2023, was terminated. Southern also entered into a real estate purchase agreement with Progressive ("Trace Hospital Sale") whereunder Progressive is to purchase certain real estate and improvements of Trace Regional Hospital, associated clinics and a vacant medical office building for $2,000 by July 31, 2024. As a result of the transactions ("Revised Agreement"), SunLink reported an impairment loss of $1,974 at December 31, 2023 to reduce the net value of the Trace hospital assets to the sale proceeds under the revised agreement and reported $58 of transaction expenses for the Revised Agreement during the quarter ended December 31, 2023. An impairment reserve of $1,695 remains at March 31, 2024 for the Trace Hospital Sale assets. During the quarter ended March 31, 2024, SunLink reported an additional loss on the sale of the Trace Hospital Sale of $613 and reported an additional $55 of transactions expenses. Southern is in the process of marketing the Trace Extended Care & Rehabilitation ("Trace Extended Care"), a skilled care nursing facility adjacent to the campus of Trace. Trace Extended Care, which Southern retains, is considered an asset held for sale at March 31, 2024. There can be no assurance that the Trace Real Estate purchase will be completed or that Trace Extended Care will be sold.

Sold Hospitals and Nursing Home– Subsidiaries of the Company have sold substantially all the assets of five (5) hospitals (“Sold Facilities”) during the period July 2, 2012 to March 17, 2019. The loss before income taxes of the Sold Facilities results primarily from the effects of retained professional liability insurance and claims expenses and settlement of a lawsuit.

Life Sciences and Engineering Segment —SunLink retained a defined benefit retirement plan which covered substantially all the employees of this segment when the segment was sold in fiscal year 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and

7

related tax benefit or expense is reflected in the results of discontinued operations for this segment for the three and nine months ended March 31, 2024 and 2023, respectively.

The components of pension expense for the three and nine months ended March 31, 2024 and 2023, respectively, were as follows:

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Interest cost	$	10		$	13		$	32		$	39
Expected return on assets		(9	)		(11	)		(27	)		(32	)
Amortization of prior service cost		0			0			0			0
Net pension expense	$	1		$	2		$	5		$	7

SunLink contributed $15 to the plan in the nine months ended March 31, 2024 and expects to contribute an additional $5 during the last three months of the fiscal year ending June 30, 2024.

Details of statements of operations from discontinued operations for the three and nine months ended March 31, 2024 and 2023, primarily reflecting the reporting of Trace as discontinued operations as a result of the Company's January 22, 2024 revised agreement to sell Trace and its plan to sell Trace Extended Care, are as follows:

	Three Months Ended							Nine Months Ended
	March 31,							March 31,
	2024				2023			2024			2023
Net Revenues	$	1,886			$	3,357		$	7,329		$	10,709
Costs and Expenses:
Salaries, wages and benefits		917				1,907			4,659			6,975
Supplies		146				237			702			910
Purchased services		280				748			1,587			2,324
Other operating expense		452				664			1,509			1,782
Rent and lease expense		8				45			75			105
Depreciation and amortization		42				98			308			297
Operating Profit (Loss)		41				(342	)		(1,511	)		(1,684	)
Other Income (Expense):
Losses on sale of assets		(613	)			0			(613	)		1
Federal stimulus - Provider relief funds		0				0			0			61
Interest income (expense), net		0				33			0			34
Loss from Discontinued Operations before income taxes		(572	)	—		(309	)		(2,124	)		(1,588	)
Impairment loss of Trace Assets and related sale expenses before income taxes		0				0			(2,032	)		0
Loss from Discontinued Operations before income taxes		(572	)			(309	)		(4,156	)		(1,588	)
Income Tax Expense		0				0			0			0
Loss from Discontinued Operations, net of tax	$	(572	)		$	(309	)	$	(4,156	)	$	(1,588	)

Details of assets and liabilities held for sale at March 31, 2024 and June 30, 2023, which primarily reflect the Trace Extended Care's assets to be sold and liabilities to be assumed as a result of the Company's January 22, 2024 revised agreement to sell the Trace hospital assets and its plans to dispose of Trace Extended Care are as follows:

8

	March 31,			June 30,
	2024			2023
Receivables - net	$	667		$	1,659
Inventory		2			125
Prepaid expense and other assets		7			136
Property, plant and equipment, net		4,529			5,564
Impairment reserve		(1,695	)		0
Right of use assets		0			246
Noncurrent assets		2			2
Total assets held for sale	$	3,512		$	7,732
Accounts payable	$	418		$	783
Accrued payroll and related taxes		91			361
Current operating lease liabilities		0			61
Other accrued expenses		54			121
Long-term operating lease liabilities		0			192
Total liabilities held for sale	$	563		$	1,518

Note 4. – Shareholders’ Equity

Stock-Based Compensation – For the three and nine months ended March 31, 2024 and 2023, the Company recognized no stock-based compensation for options issued to employees and directors of the Company. There were 9,000 shares issued as a result of options exercised during the nine months ended March 31, 2024. There were 77,452 shares issued as a result of options exercised during the nine months ended March 31, 2023.

Note 5. – Revenue and Accounts Receivable

Revenues by payor were as follows for the three and nine months ended March 31, 2002 and 2023:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Medicare	$	3,207	$	3,521	$	11,021	$	10,377
Medicaid		1,506		1,802		4,898		5,048
Retail and Institutional Pharmacy		1,517		1,632		4,839		5,666
Managed Care & Other Insurance		1,022		1,032		3,179		4,572
Self-pay		189		180		532		564
Other		21		14		58		43
Total Net Revenues	$	7,462	$	8,181	$	24,527	$	26,270

The revenues for the three months ended March 31, 2024 includes $57 of prior period sales tax refunds as a result of a reduction in the accrued sales tax liability as described in Note 10. The revenues for nine months ended March 31, 2024 includes $437 of prior period sales tax refunds, compared to $2,615 increase in revenues in the nine months ended March 31, 2023 as a result of a reduction in the accrued sales tax liability as described in Note 10.

Accounts Receivable and Allowance for Doubtful Accounts

The Company adopted Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 326, Financial Statements – Credit Losses (“Topic 326”) with an adoption date of July 1, 2023. This standard requires a financial asset (or a group of financial assets) measured at amortized cost basis, to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial assets. The Company evaluates the valuation of accounts receivable concessions allowances based upon its historical collection trends, as well as its understanding of the nature and collectability of accounts based on their age and other

9

factors. The model is based on the credit losses expected to arise over the life of the asset based on the Company’s expectations as of the balance sheet date through analyzing historical customer data as well as taking into consideration current and estimated future economic trends. The Company adopted Topic 326 and determined it did not have a material financial impact.

The roll forward of the allowance for doubtful accounts for the three and nine months ended March 31, 2024 was as follows:

June 30, 2023 balance	$	532
Concession allowance expense		79
Write-offs		(203	)
September 30, 2023 balance		408
Concession allowance expense		67
Write-offs		(104	)
December 31, 2023 balance		371
Concession allowance expense		272
Write-offs		(363	)
March 31, 2024 balance	$	280

Note 6. – Intangible Assets

As of March 31, 2024 and June 30, 2023, intangible assets consist solely of an indefinite-lived trade name of $1,180 under the Pharmacy Segment.

Amortization expense was $0 and $6 for the three months ended March 31, 2024 and 2023, respectively. Amortization expense was $0 and $19 for the three months ended March 31, 2024 and 2023, respectively.

Note 7. – Long-Term Debt

Long-term debt of discontinued operations which is included in current liabilities held for sale consisted of the following:

	March 31, 2024		June 30, 2023
Finance Lease Obligations	$	0	$	14
Less current maturities		0		(14	)
Long-term Debt	$	0	$	0

Note 8. – Income Taxes

Income tax benefit of $10 was recorded for continuing operations for the three months ended March 31, 2024. Income tax benefit of $6 (all state income benefit) was recorded for continuing operations for the three months ended March 31, 2023. Income tax benefit of $5 (all state income taxes) was recorded for continuing operations for the nine months ended March 31, 2024. Income tax benefit of $7 (all state income benefit) for continuing operations for the nine months ended March 31, 2023.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis

10

and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

At March 31, 2024, consistent with the above process, we evaluated the need for a valuation allowance against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $9,499 against the deferred tax asset so that there is no net long-term deferred income tax asset at March 31, 2024. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. A long-term deferred tax liability of $69 is recorded within other noncurrent liabilities in the accompanying condensed consolidated balance sheet of March 31, 2024 to reflect the deferred tax liability for the non-amortizing trade name intangible asset.

The principal negative evidence that led us to determine at March 31, 2024 that all the deferred tax assets should have full valuation allowances was historical tax losses and the projected current fiscal year tax loss. For purposes of evaluating our valuations allowances, the Company’s history of losses represent significant historical negative evidence and we have recognized none of our federal income tax net operating loss carry-forward of approximately $29,862.

For federal income tax purposes, at March 31, 2024, the Company had approximately $29,862 of estimated net operating loss carry-forwards available for use in future years subject to the possible limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal year 2023 through fiscal year 2038; however, with the enactment of the Tax Cut and Jobs Act on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. The Company’s returns for the periods prior to the fiscal year ended June 30, 2020 are no longer subject to potential federal and state income tax examination. Net operating loss carry-forwards generated in tax years prior to June 30, 2020 are still subject to redetermination in potential federal income tax examination.

Note 9. – Leases

The Company, as lessee, has operating leases relating to its pharmacy operations, certain medical equipment, and office equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, all of which are variable amounts based on actual costs. Variable lease costs also include escalating rent payments that are not fixed at commencement but are based on an index determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. Some leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rental rates. Leases may also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term. The components of lease cost and rent expense for the three and nine months ended March 31, 2024 and 2023 are as follows:

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
Lease Cost	March 31, 2024		March 31, 2023		March 31, 2024		March 31, 2023
Operating lease cost:
Operating lease cost	$	85	$	86	$	255	$	256
Short-term rent expense		7		5		19		18
Variable lease cost		0		1		1		2
Total operating lease cost	$	92	$	92	$	275	$	276

11

Supplemental balance sheet information relating to leases was as follows:

		As of		As of
		March 31,		June 30,
		2024		2023
Operating Leases:	Balance Sheet Classifications
Operating lease ROU Assets	ROU Assets	$	592	$	798
Current operating lease liabilities	Current operating lease liabilities		332		334
Long-term operating lease liabilities	Long-term operating lease liabilities	$	273	$	481

Supplemental cash flow and other information related to leases as of and for the three and nine months ended March 31, 2024 and 2023 are as follows:

	Three Months Ended						Nine Months Ended
Other information	March 31, 2024			March 31, 2023			March 31, 2024			March 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows of operating leases	$	85		$	86		$	255		$	256
Right-of-use assets obtained in exchange for new operating lease liabilities		0			0			18			16
Weighted-average remaining lease term:
Operating leases	1.82 years			2.74 years			1.82 years			2.74 years
Weighted-average discount rate:
Operating leases		0.98	%		1.02	%		0.98	%		1.02	%

Commitments relating to non-cancellable operating leases as of March 31, 2024 for each of the next five years and thereafter are as follows:

Payments due within	Operating Leases
1 year	$	337
2 years		252
3 years		15
4 years		10
5 years		0
Over 5 years		0
Total minimum future payments		614
Less: Imputed interest		(9	)
Total liabilities		605
Less: Current portion		(332	)
Long-term liabilities	$	273

Note 10. – Sales Tax Payable

During the fiscal year ended June 30, 2019, the Pharmacy segment business amended its sales tax position with four different taxing authorities to avail its business of exemptions from state and local sales taxes in Louisiana on revenues from the sales of products and services to beneficiaries of government insurance programs to the extent reimbursed by the administrators of such programs. No such sales taxes for any period subsequent to June 30, 2019 have been paid on the related reimbursement received from the government insurance payers’ programs with respect to sales of such products and services. The Company has filed amended sales tax returns for periods still open under the applicable statutes of limitations claiming refunds of such sales taxes paid. Refunds have been received from three taxing authorities in the amounts claimed on amended returns and a settlement was reached with one taxing authority to offset future sales tax payable. Amounts claimed and received from two taxing authorities providing refunds were recorded as revenues in the fiscal year ended June 30, 2020 in the amount of $359. During the nine months ended March

12

31, 2024, the Company recorded a refund received of $321 as revenue for a sales tax refund which was received in October 2023 and during the three months and nine months ended March 31, 2024, the Company recorded $56 and $115, respectively, for prior period sales tax settlements.

In addition, until October 1, 2022, the Company accrued as payable amounts for sales tax estimates from these taxing authorities in amounts management believed would be payable if the Company's position did not prevail. During the nine months ended March 31, 2023, after discussions with the taxing authorities and external legal counsel, the Company determined that it was more likely than not that its position could be sustained going forward and accrued but unpaid sales tax would not be payable. Based on this determination, the Company reversed $2,615 of accrued sales tax during the nine months ended March 31, 2023 as an increase of net revenues.

Note 11. – Commitments and Contingencies

The Company has no contractual obligations, commitments and contingencies related to outstanding debt and interest (excluding operating leases, see Note 9) at March 31, 2024.

Note 12. – Related Party Transactions

A director of the Company is senior counsel in a law firm which provides services to SunLink. The Company expensed an aggregate of $96 and $35 for legal services to this law firm in the three months ended March 31, 2024 and 2023, respectively and expensed an aggregate of $385 and $220 for legal services to this law firm in the nine months ended March 31, 2024 and 2023, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2024 and June 30, 2023 is outstanding legal expenses to this firm $154 and $36, respectively.

13

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “seeks to”, “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on the current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. Throughout this annual report and the notes to the condensed consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that SunLink Health Systems, Inc. or any particular subsidiary of SunLink Health Systems, Inc. owns or operates any asset, business, or property. Healthcare services, pharmacy operations and other businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc. These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors that could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance, and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•the continuing after-effects of the COVID-19 pandemic, both nationwide and in the states in which we operate, including among other things, on demand for our customary services, the efficiency of such services, availability of staffing, availability of supplies, costs and financial results. Future COVID-19, its variants or other pandemics of other contagious diseases could result in the unavailability of personnel to provide services, regulatory bans on certain services or admissions, decreased occupancy levels, increase costs, reduce our revenues and otherwise adversely affect our business;

•the competitive nature of the U.S. community hospital, extended care and rehabilitation center, nursing home, and pharmacy businesses;

•demographic characteristics and changes in areas where we operate, including resistance to vaccination for COVID-19 and/or its variants;

•the availability of cash or borrowings to fund working capital, renovations, replacements, expansions, and capital improvements at existing healthcare and pharmacy facilities and for acquisitions and replacement of such facilities;

•changes in accounting principles generally accepted in the U.S.;

•the impact of inflation on our patients, operating costs, ability and feasibility of raising funds, and on our ability to achieve cash flow and profitability, including our inability to cover cost increases because most of our revenue is from government programs whose payments are fixed; and

•fluctuations in the market value of equity securities including SunLink common shares, including fluctuations based on actual or feared inflation or recession.

Operational Factors

•the ability or inability to operate profitably in one or more segments of the healthcare business;

•the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists, and staff personnel for our operations;

14

•timeliness and amount and conditions of reimbursement payments received under government programs;

•the lack of availability of future governmental support that may be required to offset the after effects of the COVID-19 pandemic or future pandemics and absence of forgiveness features in any such future loans or an inability to meet the usage or forgiveness requirements;

•any future challenge to our compliance with requirements of the expenditure and retention of Provider Relief Funds (“PRF”) received by us;

•the ability or inability to fund our obligations under capital leases or new or existing obligations and/or any existing or potential defaults under existing indebtedness;

•restrictions imposed by existing or future contractual obligations including existing or new indebtedness;

•the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general, employment, fiduciary, other liability insurance and changes in estimates of our self-insurance claims and reserves;

•the efforts of governmental authorities, insurers, healthcare providers, and others to contain and reduce healthcare costs;

•the impact on hospital, clinic, and nursing home services of the treatment of patients in alternative or lower acuity healthcare settings, such as with drug therapy, in surgery centers, and urgent care centers, retirement homes or at home;

•changes in medical and other technology;

•increases in prices of materials and services utilized in our Healthcare Services and Pharmacy segments;

•increases in wages as a result of inflation or competition for physician, nursing, pharmacy, management, and staff positions;

•any impairment in our ability to collect accounts receivable, including deductibles and co-pay amounts;

•the functionality of or costs with respect to our information systems for our Healthcare Services and Pharmacy segments and our corporate office, including both software and hardware;

•the availability of and competition from alternative drugs or treatments to those provided by our Pharmacy segment; and

•the restrictions, clawbacks, processes, and conditions relating to our Pharmacy segment imposed by pharmacy benefit managers, drug manufacturers, and distributors.

Liabilities, Claims, Obligations and Other Matters

•claims under leases, guarantees, disposition agreements, and other obligations relating to current and future asset sales or discontinued operations, including claims from sold or leased facilities and services, retained liabilities or retained subsidiaries, and failure of buyers to satisfy liabilities for which the Company remains liable, pursuant to the disposition agreements;

•potential adverse consequences of any known and unknown government investigations;

•claims for medical malpractice product, environmental or other liabilities from continuing and discontinued operations;

•professional, general, and other claims which may be asserted against us, including claims based on a failure currently unknown to us of our physicians and other personnel to comply with COVID-19 vaccination mandates;

•potential damages and consequences of natural disasters and weather-related events such as tornados, earthquakes, hurricanes, flooding, snow, ice and wind damage, and population evacuations affecting areas in which we operate; and

•potential adverse contingencies of terrorist acts, crime or civil unrest.

15

Regulation and Governmental Activity

•negative consequences of existing and proposed governmental budgetary constraints or modification or termination of existing government programs or the implementation and related costs and disruptions of new government programs such as environmental, social and governance programs;

•negative consequences of Federal and state insurance exchanges and their rules relating to reimbursement terms;

•the continuing decision by Mississippi (where we operate our remaining nursing home) to not expand Medicaid;

•the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto, including proposed nursing home minimum staffing requirements;

•changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; indigent care and other reimbursements (e.g. Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments) and governmental assessments for such programs;

•the failure of government and private reimbursement to cover our increasing costs;

•changes in or failure to comply with Federal, state and local laws and regulations and enforcement interpretations of such laws and regulations affecting our Healthcare Services and Pharmacy segments; and

•the possible enactment of additional Federal healthcare reform laws or reform laws or regulations in states where our subsidiaries operate hospital and pharmacy facilities (including Medicaid waivers, bundled payments, managed care programs, accountable care and similar organizations, competitive bidding and other reforms).

Dispositions, Acquisition and Renovation Related Matters

•the ability to dispose of underperforming facilities, underperforming business segments and surplus assets on acceptable terms;

•the ability to complete the sale of assets pursuant to disposition agreements or the inability to collect proceeds expected pursuant to such agreements;

•the availability of cash and the terms of borrowed or equity capital to fund acquisitions or replacement facilities, improvements or renovations to existing facilities or both; and

•competition in the market for acquisitions of hospitals, rehabilitation centers, nursing homes, pharmacy facilities, and other healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner. You should read this Quarterly Report completely and with the understanding that future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. We disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information

16

on which the forward-looking statement is based, except as required by applicable law. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the other risk factors set forth elsewhere in this report.

Business Strategy: Operations, Dispositions and Acquisitions

The Board of Directors of SunLink believes Management should, among other things: (i) actively pursue one or more extraordinary corporate transactions, any of which transactions may involve (a) a merger or consolidation with a compatible third party, as a result of which the Company may not be in the majority or (b) a sale or other disposition of non-performing assets, and (ii) continue its efforts to improve its operations and services generally and achieve and maintain profitability in its existing Pharmacy business, which may include selective acquisitions, subject to available capital, (iii) pursue dispositions of underperforming subsidiaries or facilities and, (iv) effect corporate governance changes which were approved at the Special Meeting of Shareholders held on October 19, 2023, which approved reincorporation in Georgia with governing documents which provide for majority shareholder voting to better enable the Company to pursue any such extraordinary corporate transaction which may be judged favorable to the Company and its shareholders.

On January 22, 2024, the Company's indirect subsidiary, Southern Health Corporation of Houston, Inc. (“Southern”), reached revised agreements for the sale of Trace Regional Hospital, a vacant medical office building and three (3) patient clinics in Chickasaw County, MS, (collectively “Trace”) to Progressive Health of Houston, LLC (“Progressive”) pursuant to which Southern sold certain personal and intangible property to Progressive for $500 under to an asset purchase agreement ('Trace Assets Sale"), entered into a six-month net lease of certain hospital real property for $20 per month, and engaged Progressive under a management agreement to manage the operations of Trace pending receipt of certain regulatory approvals, which was received February 29, 2024. Southern also entered into a real estate purchase agreement with Progressive ("Trace Hospital Sale") whereby Progressive is to purchase certain real estate and improvements of Trace for $2,000 by July 31, 2024. Southern is in the process of marketing for sale the Trace Extended Care & Rehabilitation ("Trace Extended Care"), a skilled care nursing facility adjacent to the campus of Trace. Trace Extended Care, which Southern retains, is considered an asset held for sale at March 31, 2024. There can be no assurance any extraordinary corporate transaction, the Trace Hospital Sale or the sale of Trace Extended Care will be completed.

The Company expects to use existing cash primarily to sustain its operations, and to fund activities related to such extraordinary transactions when available and appropriate, and for other general corporate purposes. The Company believes certain portions of its businesses continue to under-perform and the Company periodically entertains overtures for the sale of one or more of its businesses when deemed appropriate, including to better position the company for an extraordinary corporate business transaction such as a merger or consolidation.

In connection with a Special Meeting of Shareholders to reincorporate in Georgia and approve majority voting, a total of 7,032 Series C Preferred Shares were issued, each entitled to one million (1,000,000) votes and in turn each Series C Fractional Interest in such a Series C Preferred Share was issued for each Common Share of the Company and accordingly was entitled to one thousand (1,000) votes out of such one million votes of the corresponding Series C Preferred. Series C Fractional Interests could not be transferred separately from the Common Shares and were represented by the Common Shares. A further description of the Series C Preferred Shares and the Series C Fractional Interests and the terms and provisions thereof is set forth in the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2023. Each Common Share was entitled to one (1) vote as a Common Share and also one thousand (1,000) votes for the corresponding Series C Fractional Interest thereon, on each matter properly brought before the special shareholders’ meeting which was held on October 19, 2023 and at which shareholder approval of the Company's reincorporation from the state of Ohio to Georgia (the “Special Meeting”). The Series C Fractional Interests were automatically redeemed and the Series C Preferred Shares were cancelled.

There is no assurance that any strategic transaction will be authorized by the Company's Board of Directors or, if authorized, that any such transaction will be completed.

After Effects of COVID-19 Pandemic

17

The Company continued to experience adverse after-effects of the COVID-19 pandemic in the quarter ended March 31, 2024 and believes such effects will likely continue to affect its assets and operations in the foreseeable future particularly salaries and wages pressure, workforce shortages, supply chain disruption and broad inflationary pressures. Our ability to make estimates of any such continuing effects of evolving strains of COVID-19 on future revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is very limited, depending as they do on the severity and length thereof; as well as any further government actions and/or regulatory changes intended to address such effects.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made; and changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2023 Annual Report on Form 10-K and continue to include the following areas: receivables – net and provision for doubtful accounts; revenue recognition and net patient service revenues; goodwill, intangible assets and accounting for business combinations; professional and general liability claims; and accounting for income taxes. There have been no material changes in our critical accounting estimates for the periods presented other than amounts readily computable from the financial statements included in this form 10-Q.

Financial Summary

Results of Operations

The Company’s operations for the three and nine months ended March 31, 2024 continued to be negatively impacted by the effects of the aftermath of the COVID-19 pandemic, although mitigated somewhat from prior quarters, including among other factors, difficulty hiring qualified employees, rising labor and supply costs and supply chain challenges resulting in inability to obtain pharmacy and DME products on a timely, cost effective basis.

	Three Months Ended									Nine Months Ended
	March 31,									March 31,
	2024			2023			% Change			2024			2023			% Change
Net Revenues	$	7,462		$	8,181			(8.8	)%	$	24,527		$	26,270			(6.6	)%
Costs and expenses		(8,334	)		(8,648	)		(3.6	)%		(26,263	)		(25,084	)		4.7	%
Operating profit (loss)		(872	)		(467	)		86.7	%		(1,736	)		1,186			(246.4	)%
Interest income (expense) - net		19			8			137.5	%		70			13			438.5	%
Gain on sale of assets		0			0		NA				2			13			(84.6	)%
Earnings (Loss) from continuing operations before income taxes	$	(853	)	$	(459	)		85.8	%	$	(1,664	)	$	1,212			(237.3	)%

18

Our net revenues are from two businesses, pharmacy and a subsidiary which provides information technology services to outside customers and SunLink subsidiaries. The Company’s revenues by payor were as follows for the three and nine months ended March 31, 2024 and 2023:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Medicare	$	3,207	$	3,521	$	11,021	$	10,377
Medicaid		1,506		1,802		4,898		5,048
Retail and Institutional Pharmacy		1,517		1,632		4,839		5,666
Managed Care & Other Insurance		1,022		1,032		3,179		4,572
Self-pay		189		180		532		564
Other		21		14		58		43
Total Net Revenues	$	7,462	$	8,181	$	24,527	$	26,270

Pharmacy net revenues for the three month period ended March 31, 2024 decreased $729 or 9% from the three month period ended March 31, 2023 and decreased $1,711 or 7% from the nine month period ended March 31, 2024 from the nine month period ended March 31, 2023. The revenues for the three months ended March 31, 2024 include $57 of prior period sales tax refunds and the revenues for the nine months ended March 31, 2024 include $437 of prior period sales tax refunds. The decreased net revenues this year results primarily from the recognition of prior periods' accrued sales tax of $2,615 in the nine months ended March 31, 2023. The decrease in Pharmacy net revenues for the three months period ended March 31, 2024 compared to the same period last fiscal year resulted from lower retail pharmacy scripts filled and durable medical equipment ("DME") orders shipped. The decrease in Pharmacy net revenues for the nine months period ended March 31, 2024 compared to the same period last fiscal year resulted primary from the $2,615 recognition of prior periods accrued sales compare to $437 in prior periods sales tax refunds received this fiscal year.

Costs and expenses, including depreciation and amortization, were $8,334 and $8,648 for the three months ended March 31, 2024 and 2023, respectively. Costs and expenses, including depreciation and amortization, were $26,263 and $25,084 for the nine months ended March 31, 2024 and 2023, respectively.

	Cost and Expenses as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Cost of goods sold		58.2	%		58.1	%		56.5	%		51.9	%
Salaries, wages and benefits		35.5	%		31.1	%		32.4	%		28.7	%
Supplies		0.5	%		0.8	%		0.4	%		0.4	%
Purchased services		3.6	%		3.7	%		3.4	%		3.0	%
Other operating expenses		7.9	%		7.4	%		9.3	%		7.1	%
Rent and lease expense		1.2	%		1.1	%		1.1	%		1.1	%
Depreciation and amortization expense		4.6	%		3.9	%		3.9	%		3.3	%

19

Almost all categories of costs and expenses increased as a percent of net revenues in the three and nine months ended March 31, 2024 compared to the prior fiscal year due to the decreased net revenues this year and revenues last year which included the sales tax recognition of $2,615, and due to the corporate overhead costs this year of a public company in relation to the Company's smaller size. Cost of goods sold increased in total due to higher cost of certain pharmaceuticals and DME products which resulted from supply chain issues. Salaries, wages and benefits ("SWB")increased in total for the three and nine months ended March 31, 2024 compared to the prior period last year due to higher salaries and wages required in connection with current labor markets and operating challenges of labor allocation relating to the pandemic effects, including the use of contract labor. Other operating expenses for the nine months ending March 31, 2024 increased from the prior year's comparable period primarily due to increased legal expenses relating to the change in state of incorporation from Ohio to Georgia, which was finalized in October 2023. Depreciation expense also increased this year due to the $1,337 of pharmacy capital expenditures last fiscal year.

Operating Profit (Loss)

The Company reported an operating loss of $853 for the three months period ended March 31, 2024 compared to an operating loss of $467 for the three months period ended March 31, 2023. The increased operating loss for the three months ended March 31, 2024 compared to the three months period ended March 31, 2023 resulted from the 9% decrease in net revenues this quarter and increased costs as a percentage of net revenues. The Company reported an operating loss of $1,736 for the nine months period ended March 31, 2024 compared to an operating profit of $1,186 for the nine months period ended March 31, 2023. The $2.922 increased operating loss for the nine months ended March 31, 2024 compared to the nine months period ended March 31, 2023 resulted primarily from the 7% decrease in net revenues during the current nine month period and increased costs as a percentage of net revenues.

Income Taxes

Income tax benefit of $10 was recorded for continuing operations for the three months ended March 31, 2024. Income tax benefit of $6 (all state income benefit) was recorded for continuing operations for the three months ended March 31, 2023. Income tax benefit of $5 (all state income taxes) was recorded for continuing operations for the nine months ended March 31, 2024. Income tax benefit of $7 (all state income benefit) for continuing operations for the nine months ended March 31, 2023.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

At March 31, 2024, consistent with the above process, we evaluated the need for a valuation allowance against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $9,499 against the deferred tax asset so that there is no net long-term deferred income tax asset at March 31, 2024. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. A long-term deferred tax liability of $69 is recorded within other noncurrent liabilities in the accompanying condensed consolidated balance sheet of March 31, 2024 to reflect the deferred tax liability for the non-amortizing trade name intangible asset.

The principal negative evidence that led us to determine at March 31, 2024 that all the deferred tax assets should have full valuation allowances was historical tax losses and the projected current fiscal year tax loss. For purposes of evaluating our valuations allowances, the Company’s history of losses represent significant historical negative

20

evidence and we have recognized none of our federal income tax net operating loss carry-forward of approximately $29,862

For federal income tax purposes, at March 31, 2024, the Company had approximately $29,862 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal year 2023 through fiscal year 2038; however, with the enactment of the Tax Cut and Jobs Act on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. The Company’s returns for the periods prior to the fiscal year ended June 30, 2020 are no longer subject to potential federal and state income tax examination. Net operating loss carry-forwards generated in tax years prior to June 30, 2020 are still subject to redetermination in potential federal income tax examination.

Loss from Discontinued Operations after Income Taxes

The loss from discontinued operations after income taxes was $572 for the three month period ended March 31, 2024 compared to a loss from discontinued operations after income taxes of $309 for the three month period ended March 31, 2023. The increased loss this year included a loss of $613 on the sale of Trace Hospital Sale which included $103 for sale transaction costs. The loss from discontinued operations after income taxes was $4,156 for the nine month period ended March 31, 2024 compared to a loss from discontinued operations after income taxes of $1,588 for the nine month period ended March 31, 2023.

Discontinued Operations

All of the businesses discussed below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Sale of Trace Regional Hospital, medical office building and three patient clinics, Trace Extended Care operations

On January 22, 2024, the Company's indirect subsidiary, Southern Health Corporation of Houston, Inc. (“Southern”), reached a revised agreement for the sale of Trace Regional Hospital, a vacant medical office building and three (3) patient clinics in Chickasaw County, MS, (collectively “Trace”) to Progressive Health of Houston, LLC (“Progressive”). Pursuant to those agreements, Southern sold certain personal and intangible property to Progressive on January 22, 2024 for $500 pursuant to an asset purchase agreement ('Trace Assets Sale"), entered into a six-month net lease of certain hospital real property for $20 per month, and engaged Progressive under a management agreement to manage the operations of Trace pending receipt of certain regulatory approvals, which was received February 29, 2024. As a result of the transaction, Southern’s previous agreement with Progressive dated November 10, 2023, was terminated. Southern also entered into a real estate purchase agreement with Progressive ("Trace Hospital Sale") whereunder Progressive is to purchase certain real estate and improvements of Trace for $2,000 by July 31, 2024. As a result of the transactions ("Revised Agreement"), SunLink reported an impairment loss of $1,974 at December 31, 2023 to reduce the net value of the Trace hospital assets to the sale proceeds under the revised agreement and reported $58 of transaction expenses for the Revised Agreement during the quarter ended December 31, 2023. An impairment reserve of $$1,695 remains at March 31, 2024 for the Trace Hospital Sale assets. During the quarter ended March 31, 2024, SunLink reported an additional loss on the sale of the Trace Hospital Sale of $613 and reported as additional $55 of transactions expenses. Southern is in the process of marketing the Trace Extended Care & Rehabilitation ("Trace Extended Care"), a skilled care nursing facility adjacent to the campus of Trace. Trace Extended Care, which Southern retains, is considered an asset held for sale at March 31, 2024. Southern is in the process of marketing for sale Trace Extended Care, which Southern retains. There can be no assurance that the Trace Real Estate purchase will be completed or that Trace Extended Care will be sold.

Sold Hospitals and Nursing Home – Subsidiaries of the Company have sold substantially all the assets of five rural hospitals (“Sold Facilities”) during the period July 2, 2012 to March 17, 2019. The loss before income taxes of the Sold Facilities results primarily from the effects of retained professional liability insurance and claims expenses and settlement of a lawsuit.

21

Net Loss

Net loss for the three months period ended March 31, 2024 was $1,396 (or a loss of $0.20 per fully diluted share) as compared to a net loss of $762 (or $0.11 per fully diluted share) for the three months period ended March 31, 2023. Net loss for the nine months period ended March 31, 2024 was $5,815 (or a loss of $0.83 per fully diluted share) as compared to a net loss of $369 (or $0.05 per fully diluted share) for the nine months period ended March 31, 2023.

Liquidity and Capital Resources

Overview

The Company and its subsidiaries' primary source of liquidity for working capital and operational needs, to pursue extraordinary corporate transactions and for general corporate purposes, is unrestricted cash on hand, which was $1,211 at March 31, 2024, and the sale of assets. From time-to-time, we may, nevertheless, seek to obtain financing for the liquidity needs of the Company or individual subsidiaries

CARES Act Funds - The CARES Act was enacted by the U.S. government on March 27, 2020 provided the relief to health care providers under the CARES Act in the form of grants under PRF and forgivable loans under PPP. We received a total of $9,416 under the CARES Act programs consisting of $6,182 in general and targeted PRF and $3,234 of PPP loans. During the first two calendar quarters of 2021, the Company became eligible for, and we applied for $3,586 of ERC through amended quarterly payroll tax filings, all of which the Company has received as of the date of this filing.

Subject to the effects, risks and uncertainties associated with the aftermath of the COVID-19 pandemic and our ability to retain the CARES funds described above, as well as our ability to complete the disposition of certain unprofitable operations, including the Trace transaction, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to outstanding debt, noncancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2024 were as follows:

Payments due within:	Operating Leases
1 year	$	337
2 years		252
3 years		15
4 years		10
5 years		0
Over 5 years		0
	$	614

As of March 31, 2024, we had no outstanding debt.

The Company currently expects to purchase approximately $800 of capitalizable DME by the Pharmacy segment (to be rented to customers) during the next twelve months. The timing and actual amount which will be expended is difficult to predict due to various factors including varying demand for such equipment as well as its availability given current supply sourcing challenges. Other capital expenditures for replacement and upgrade of current facilities and equipment of the Pharmacy business may be needed during the next twelve months although there is no estimate of those expenditures other than being expected to be at a lower level than fiscal years 2023 and 2022. The Company anticipates funding such expenditures primarily from cash on hand. Other cash expenditures for the next twelve months currently are expected to be in-line with expenditures for the nine months ended March 31, 2024, subject to further operating and administrative cost increases, and other settlements of cost reports and other liabilities in the ordinary course of business as well as cash receipts and disbursements relating to possible asset sales, and, additionally, the Company’s ability to retain unrecognized CARES Act grants, PPP funds and ERC funds received or previously received. Other than reported above, there have been no material changes outside the ordinary course of business relating to our upcoming cash obligations which have occurred during the three months ended March 31, 2024. Other than with

22

respect to scheduled cash expenditures (based on current operating levels) for long-term debt, operating leases, and the specific items previously disclosed here, as well as continued uncertainties relating to the aftermath of the COVID-19 pandemic and asset sales, the Company is currently unaware of other trends or unusual uncertainties that are likely to cause a material change in its cash expenditures in periods beyond the next twelve months. See Notes 7, 9, 10, and 11 to our financial statements. The Company is also unaware of events that are reasonably likely to cause a material change in the relationship between its costs and revenues (such as known or reasonably likely future increases in costs of labor or materials, price increases or inventory adjustments, beyond those discussed herein); however, we are unable to predict with any degree of accuracy when, or the extent to which, recent inflationary price trends, labor disruptions and supply chain challenges experienced in 2021, 2022 and 2023 to date will mitigate.

Related Party Transactions

A director of the Company is senior counsel in a law firm which provides services to SunLink. The Company expensed an aggregate of $96 and $35 for legal services to this law firm in the three months ended March 31, 2024 and 2023, respectively and expensed an aggregate of $385 and $220 for legal services to this law firm in the nine months ended March 31, 2024 and 2023, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2024 and June 30, 2023 is outstanding legal expenses to this firm $154 and $36, respectively.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our chief executive officer and chief financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of March 31, 2024

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2024. The effect, if any, of the COVID-19 pandemic on the effectiveness of current disclosure controls and procedures in future periods is uncertain and we intend to revise the same, if any, and to the extent deemed appropriate.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended March 31, 2024 in our internal control over financial reporting that materially affected, or is believed likely to materially affect, our internal controls over financial reporting. Notwithstanding staff absences and turnover and challenges hiring new and replacement staff, including in our financial departments, to date, we do not believe the COVID-19 pandemic has had any material effect on the effectiveness of our

23

disclosure controls and procedures, however we cannot assure you that our internal controls will not be affected in the case of other or recurrent pandemics.

24

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1. LEGAL PROCEEDINGS

The Company and its subsidiaries are subject to various claims and litigation that arise from time to time in the ordinary course of business, including, among other things, tax, contract, workers compensation and medical malpractice claims and other claims and litigation. Medical malpractice and certain other claims are generally covered by malpractice, general liability or other insurance but are subject to provisions under which the Company retains a portion of the risk, which retention, particularly in the case of claims of medical malpractice, can be material. Based on current knowledge, the Company’s management does not believe that any current pending legal proceedings will have a material adverse effect on the Company’s consolidated financial position or its liquidity. However, in light of the uncertainties involved and indeterminate damages sought in some such legal proceedings, an adverse outcome could be material to our results of operations or cash flows in any reporting period.

ITEM 1A. RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A - Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2023. We believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein.
 

In addition to the matters set forth herein, the reader should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report that could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we," "our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6. EXHIBITS

Exhibits:

31.1	Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
31.2	Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
32.1	Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following materials from the Company’s Quarterly Report on Form 10-Q for the three and nine months ended March 31, 2024, formatted in iXBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and June 30, 2023, (ii) Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the three and nine months ended March 31, 2024 and 2023 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three and nine months ended March 31, 2024 and 2022 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

25

104 Cover Page Interactive Data File (formatted as Inline XRBL with the applicable taxonomy extension information in Exhibit 101.)

26

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SunLink Health Systems, Inc.
By:	/s/ Mark J. Stockslager
	Mark J. Stockslager
	Chief Financial Officer

Dated: May 15, 2024

27

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2024 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, and is not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of March 31, 2024 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 15, 2024	/s/ Robert M. Thornton, Jr.
	Robert M. Thornton, Jr.
	SunLink Health Systems, Inc.
	Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2024 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, and is not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of March 31, 2024 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 15, 2024	/s/ Mark J. Stockslager
	Mark J. Stockslager
	SunLink Health Systems, Inc.
	Chief Financial Officer

EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 15, 2024	/s/ Robert M. Thornton, Jr.
	Robert M. Thornton, Jr.
	SunLink Health Systems, Inc.
	Chief Executive Officer

EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024 as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 15, 2024	/s/ Mark J. Stockslager
	Mark J. Stockslager
	SunLink Health Systems, Inc.
	Chief Financial Officer

XML

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2024	May 14, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--06-30
Entity Registrant Name	SUNLINK HEALTH SYSTEMS, INC.
Entity Central Index Key	0000096793
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	1-12607
Entity Incorporation, State or Country Code	GA
Entity Tax Identification Number	31-0621189
Entity Address, Address Line One	900 Circle 75 Parkway
Entity Address, Address Line Two	Suite 690
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	770
Local Phone Number	933-7000
Entity Common Stock, Shares Outstanding		7,040,603
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares without par value
Trading Symbol	SSY
Security Exchange Name	NYSEAMER
Preferred Share Purchase Rights [Member]
Document Information [Line Items]
Title of 12(b) Security	Preferred Share Purchase Rights
No Trading Symbol Flag	true

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Current Assets:
Cash and cash equivalents	$ 1,211	$ 4,486
Receivables - net	3,078	2,592
Inventory	1,561	1,628
Current assets held for sale	3,512	1,920
Prepaid expense and other assets	1,604	1,648
Total current assets	10,966	12,274
Property, plant and equipment, at cost	12,302	11,259
Less accumulated depreciation	(9,399)	(8,542)
Property, plant and equipment - net	2,903	2,717
Noncurrent assets:
Intangible assets	1,180	1,180
Noncurrent assets held for sale	0	5,812
Right of use assets	592	798
Other noncurrent assets	503	487
Total noncurrent assets	2,275	8,277
TOTAL ASSETS	16,144	23,268
Current Liabilities:
Accounts payable	1,532	1,067
Accrued payroll and related taxes	857	1,027
Current liabilities held for sale	563	1,326
Current operating lease liabilities	332	334
Other accrued expenses	675	1,115
Total current liabilities	3,959	4,869
Long-Term Liabilities
Noncurrent liability for professional liability risks	231	138
Long-term operating lease liabilities	273	481
Noncurrent liabilities held for sale	0	192
Other noncurrent liabilities	73	171
Total long-term liabilities	577	982
Commitments and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 7,041 shares at March 31, 2024 and 7,032 at June 30, 2023	3,521	3,516
Additional paid-in capital	10,747	10,746
Retained earnings (deficit)	(2,810)	3,005
Accumulated other comprehensive income	150	150
Total Shareholders’ Equity	11,608	17,417
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 16,144	$ 23,268

XML

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	7,041,000	7,032,000
Common shares, outstanding	7,041,000	7,032,000

XML

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net revenues	$ 7,462	$ 8,181	$ 24,527	$ 26,270
Costs and Expenses:
Salaries, wages and benefits	2,652	2,543	7,937	7,547
Supplies	36	39	109	104
Other operating expenses	589	601	2,279	1,854
Rent and lease expense	92	92	275	276
Depreciation and amortization	342	316	960	873
Operating Profit (loss)	(853)	(467)	(1,736)	1,186
Other Income (Expense):
Gains on sale of assets	0	0	2	13
Interest income (expense), net	19	8	70	13
Earnings (Loss) from Continuing Operations before income taxes	(834)	(459)	(1,664)	1,212
Income Tax Benefit	(10)	(6)	(5)	(7)
Earnings (Loss) from Continuing Operations	(824)	(453)	(1,659)	1,219
Loss from Discontinued Operations, net of tax	(572)	(309)	(4,156)	(1,588)
Net Loss	(1,396)	(762)	(5,815)	(369)
Other comprehensive income	0	0	0	0
Comprehensive Loss	$ (1,396)	$ (762)	$ (5,815)	$ (369)
Continuing Operations:
Basic	$ (0.12)	$ (0.06)	$ (0.24)	$ 0.17
Diluted	(0.12)	(0.06)	(0.24)	0.17
Discontinued Operations:
Basic	(0.08)	(0.04)	(0.59)	(0.23)
Diluted	(0.08)	(0.04)	(0.59)	(0.23)
Net Loss:
Basic	(0.2)	(0.11)	(0.83)	(0.05)
Diluted	$ (0.2)	$ (0.11)	$ (0.83)	$ (0.05)
Weighted-Average Common Shares Outstanding:
Basic	7,041	7,032	7,038	7,015
Diluted	7,041	7,032	7,038	7,018
Product [Member]
Costs and Expenses:
Cost of goods sold	$ 4,339	$ 4,755	$ 13,871	$ 13,642
Service [Member]
Costs and Expenses:
Cost of goods sold	$ 265	$ 302	$ 832	$ 788

XML

Condensed Consolidated Statements Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Loss) [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Jun. 30, 2022	$ 19,120	$ 3,478	$ 10,736	$ 4,800	$ 106
Beginning Balance,Shares at Jun. 30, 2022		6,954,000
Share options exercised	48	$ 38	10	0	0
Share options exercised, Shares		78,000
Net earnings (loss)	(1,558)	$ 0	0	(1,558)	0
Ending Balance at Sep. 30, 2022	17,610	$ 3,516	10,746	3,242	106
Ending Balance, Shares at Sep. 30, 2022		7,032,000
Beginning Balance at Jun. 30, 2022	$ 19,120	$ 3,478	10,736	4,800	106
Beginning Balance,Shares at Jun. 30, 2022		6,954,000
Share options exercised, Shares	77,452
Net earnings (loss)	$ (369)
Ending Balance at Mar. 31, 2023	18,799	$ 3,516	10,746	4,431	106
Ending Balance, Shares at Mar. 31, 2023		7,032,000
Beginning Balance at Sep. 30, 2022	17,610	$ 3,516	10,746	3,242	106
Beginning Balance,Shares at Sep. 30, 2022		7,032,000
Net earnings (loss)	1,951	$ 0	0	1,951	0
Ending Balance at Dec. 31, 2022	19,561	$ 3,516	10,746	5,193	106
Ending Balance, Shares at Dec. 31, 2022		7,032,000
Net earnings (loss)	(762)	$ 0	0	(762)	0
Ending Balance at Mar. 31, 2023	18,799	$ 3,516	10,746	4,431	106
Ending Balance, Shares at Mar. 31, 2023		7,032,000
Beginning Balance at Jun. 30, 2023	$ 17,417	$ 3,516	10,746	3,005	150
Beginning Balance,Shares at Jun. 30, 2023	7,032,000	7,032,000
Share options exercised	$ 6	$ 5	1	0	0
Share options exercised, Shares		9,000
Net earnings (loss)	(1,344)	$ 0	0	(1,344)	0
Ending Balance at Sep. 30, 2023	16,079	$ 3,521	10,747	1,661	150
Ending Balance, Shares at Sep. 30, 2023		7,041,000
Beginning Balance at Jun. 30, 2023	$ 17,417	$ 3,516	10,746	3,005	150
Beginning Balance,Shares at Jun. 30, 2023	7,032,000	7,032,000
Share options exercised, Shares	9,000
Net earnings (loss)	$ (5,815)
Ending Balance at Mar. 31, 2024	$ 11,608	$ 3,521	10,747	(2,810)	150
Ending Balance, Shares at Mar. 31, 2024	7,041,000	7,041,000
Beginning Balance at Sep. 30, 2023	$ 16,079	$ 3,521	10,747	1,661	150
Beginning Balance,Shares at Sep. 30, 2023		7,041,000
Net earnings (loss)	(3,075)	$ 0	0	(3,075)	0
Ending Balance at Dec. 31, 2023	13,004	$ 3,521	10,747	(1,414)	150
Ending Balance, Shares at Dec. 31, 2023		7,041,000
Net earnings (loss)	(1,396)	$ 0	0	(1,396)	0
Ending Balance at Mar. 31, 2024	$ 11,608	$ 3,521	$ 10,747	$ (2,810)	$ 150
Ending Balance, Shares at Mar. 31, 2024	7,041,000	7,041,000

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Cash Flows [Abstract]
Net Cash Used in Operating Activities	$ (2,592)	$ (119)
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations	(1,089)	(969)
Expenditures for property, plant and equipment - discontinued operations	(91)	(556)
Proceeds from sale of property, plant and equipment - continuing operations	5	213
Proceeds from sale of Trace hospital operations - discontinued operations	500	0
Net Cash Used in Investing Activities	(675)	(1,312)
Cash Flows Provided by (Used in) Financing Activities:
Proceeds from share options exercises	6	49
Payments on long-term debt - discontinued operations	(14)	(30)
Net Cash Provided by (Used in) Financing Activities	(8)	19
Net Decrease in Cash and Cash Equivalents	(3,275)	(1,412)
Cash and Cash Equivalents Beginning of Period	4,486	6,794
Cash and Cash Equivalents End of Period	1,211	5,382
Cash Paid (Received) for:
Interest	(70)	(46)
Income taxes	105	(32)
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	$ 18	$ 24

XML

Basis of Presentation

9 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2024 and for the three and nine month periods ended March 31, 2024 and 2023 have been prepared in accordance with Rule 8-03 and Article 8-03 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2023 balance sheet included in this interim filing has been derived from the audited consolidated financial statements at that date but does not include all the information and related notes required by GAAP for complete consolidated financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the SEC on September 28, 2023. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2024 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Throughout these notes to the condensed consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that SunLink Health Systems, Inc. or any particular subsidiary of the Company owns or operates any particular asset, business or property. Each operation and business described in this filing is owned and operated by a distinct and indirect subsidiary of SunLink Health Systems, Inc.

XML

Business Operations

9 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Operations

Note 2. – Business Operations

The Company’s continuing operations are composed of a pharmacy business and an information technology (“IT”) business.

The pharmacy business, is composed of four operational areas conducted in three locations in southwest Louisiana:

· Retail pharmacy products and services, consisting of retail pharmacy sales.

· Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.

· Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes.

· Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.

A subsidiary, SunLink Health Systems Technology (“SHST Technology”), provides information technology (“IT”) services to outside customers and to SunLink subsidiaries. The Company also owns a subsidiary which owns approximately twenty-five (25) acres of unimproved land in Ellijay, Georgia.

Series C Redeemable Preferred Shares

On August 2, 2023, the Board of SunLink declared a non-cash dividend per Common Share of one fractional interest in one of the Corporation’s Series C Redeemable Preferred Shares (the “Series C Preferred Shares” and each such

fraction of a Series C Preferred Share, a “Series C Fractional Interest”). Each of the 7,032 Series C Preferred Shares issued was entitled to one million (1,000,000) votes and each Series C Fractional Interest in a Series C Preferred Share was entitled to one thousand (1,000) votes out of such one million votes. Series C Fractional Interests could not be transferred separately from the Common Shares and were represented by the Common Shares. A further description of the Series C Preferred Shares and the Series C Fractional Interests and the terms and provisions thereof is set forth in the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2023. Each Common Share was entitled to one (1) vote as a Common Share and also one thousand (1,000) votes for the corresponding Series C Fractional Interest thereon, on each matter properly brought before a special shareholders’ meeting which was held on October 19, 2023 and at which the Corporation was reincorporated from the state of Ohio to Georgia (the “Special Meeting”). The Series C Fractional Interests were automatically redeemed and the Series C Preferred Shares cancelled.

COVID-19 Pandemic and CARES Act Funding

The Company continued to experience adverse after-effects of the COVID-19 pandemic in the quarter ended March 31, 2024 and believes such effects will likely continue to affect its assets and operations in the foreseeable future, particularly salaries and wages pressure, workforce shortages, supply chain disruption and broad inflationary pressures. Our ability to make estimates of any such continuing effects from current or evolving strains of COVID-19 on future revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is limited, depending, as they do, on the severity and length thereof; as well as any further government actions and/or regulatory changes intended to address such effects.

XML

Discontinued Operations

9 Months Ended

Mar. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

All of the businesses discussed below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Sale of Trace Regional Hospital, medical office building and three patient clinics, Trace Extended Care operations –On January 22, 2024, the Company's indirect subsidiary, Southern Health Corporation of Houston, Inc. (“Southern”), reached a revised agreement for the sale of Trace Regional Hospital, a medical office building and three (3) patient clinics in Chickasaw County, MS, (collectively “Trace”) to Progressive Health of Houston, LLC (“Progressive”). Pursuant to those agreements, Southern sold certain personal and intangible property of Trace Regional Hospital and associated clinics to Progressive on January 22, 2024 for $500 pursuant to an asset purchase agreement ('Trace Assets Sale"), entered into a six-month net lease of certain hospital real property for $20 per month, and engaged Progressive under a management agreement to manage the operations of Trace pending receipt of certain regulatory approvals, which was received February 29, 2024. As a result of the transaction, Southern’s previous agreement with Progressive dated November 10, 2023, was terminated. Southern also entered into a real estate purchase agreement with Progressive ("Trace Hospital Sale") whereunder Progressive is to purchase certain real estate and improvements of Trace Regional Hospital, associated clinics and a vacant medical office building for $2,000 by July 31, 2024. As a result of the transactions ("Revised Agreement"), SunLink reported an impairment loss of $1,974 at December 31, 2023 to reduce the net value of the Trace hospital assets to the sale proceeds under the revised agreement and reported $58 of transaction expenses for the Revised Agreement during the quarter ended December 31, 2023. An impairment reserve of $1,695 remains at March 31, 2024 for the Trace Hospital Sale assets. During the quarter ended March 31, 2024, SunLink reported an additional loss on the sale of the Trace Hospital Sale of $613 and reported an additional $55 of transactions expenses. Southern is in the process of marketing the Trace Extended Care & Rehabilitation ("Trace Extended Care"), a skilled care nursing facility adjacent to the campus of Trace. Trace Extended Care, which Southern retains, is considered an asset held for sale at March 31, 2024. There can be no assurance that the Trace Real Estate purchase will be completed or that Trace Extended Care will be sold.

Sold Hospitals and Nursing Home– Subsidiaries of the Company have sold substantially all the assets of five (5) hospitals (“Sold Facilities”) during the period July 2, 2012 to March 17, 2019. The loss before income taxes of the Sold Facilities results primarily from the effects of retained professional liability insurance and claims expenses and settlement of a lawsuit.

Life Sciences and Engineering Segment —SunLink retained a defined benefit retirement plan which covered substantially all the employees of this segment when the segment was sold in fiscal year 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and

related tax benefit or expense is reflected in the results of discontinued operations for this segment for the three and nine months ended March 31, 2024 and 2023, respectively.

The components of pension expense for the three and nine months ended March 31, 2024 and 2023, respectively, were as follows:

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Interest cost	$	10		$	13		$	32		$	39
Expected return on assets		(9	)		(11	)		(27	)		(32	)
Amortization of prior service cost		0			0			0			0
Net pension expense	$	1		$	2		$	5		$	7

SunLink contributed $15 to the plan in the nine months ended March 31, 2024 and expects to contribute an additional $5 during the last three months of the fiscal year ending June 30, 2024.

Details of statements of operations from discontinued operations for the three and nine months ended March 31, 2024 and 2023, primarily reflecting the reporting of Trace as discontinued operations as a result of the Company's January 22, 2024 revised agreement to sell Trace and its plan to sell Trace Extended Care, are as follows:

	Three Months Ended							Nine Months Ended
	March 31,							March 31,
	2024				2023			2024			2023
Net Revenues	$	1,886			$	3,357		$	7,329		$	10,709
Costs and Expenses:
Salaries, wages and benefits		917				1,907			4,659			6,975
Supplies		146				237			702			910
Purchased services		280				748			1,587			2,324
Other operating expense		452				664			1,509			1,782
Rent and lease expense		8				45			75			105
Depreciation and amortization		42				98			308			297
Operating Profit (Loss)		41				(342	)		(1,511	)		(1,684	)
Other Income (Expense):
Losses on sale of assets		(613	)			0			(613	)		1
Federal stimulus - Provider relief funds		0				0			0			61
Interest income (expense), net		0				33			0			34
Loss from Discontinued Operations before income taxes		(572	)	—		(309	)		(2,124	)		(1,588	)
Impairment loss of Trace Assets and related sale expenses before income taxes		0				0			(2,032	)		0
Loss from Discontinued Operations before income taxes		(572	)			(309	)		(4,156	)		(1,588	)
Income Tax Expense		0				0			0			0
Loss from Discontinued Operations, net of tax	$	(572	)		$	(309	)	$	(4,156	)	$	(1,588	)

Details of assets and liabilities held for sale at March 31, 2024 and June 30, 2023, which primarily reflect the Trace Extended Care's assets to be sold and liabilities to be assumed as a result of the Company's January 22, 2024 revised agreement to sell the Trace hospital assets and its plans to dispose of Trace Extended Care are as follows:

	March 31,			June 30,
	2024			2023
Receivables - net	$	667		$	1,659
Inventory		2			125
Prepaid expense and other assets		7			136
Property, plant and equipment, net		4,529			5,564
Impairment reserve		(1,695	)		0
Right of use assets		0			246
Noncurrent assets		2			2
Total assets held for sale	$	3,512		$	7,732
Accounts payable	$	418		$	783
Accrued payroll and related taxes		91			361
Current operating lease liabilities		0			61
Other accrued expenses		54			121
Long-term operating lease liabilities		0			192
Total liabilities held for sale	$	563		$	1,518

XML

Shareholders' Equity

9 Months Ended

Mar. 31, 2024

Federal Home Loan Banks [Abstract]

Shareholders' Equity

Note 4. – Shareholders’ Equity

Stock-Based Compensation – For the three and nine months ended March 31, 2024 and 2023, the Company recognized no stock-based compensation for options issued to employees and directors of the Company. There were 9,000 shares issued as a result of options exercised during the nine months ended March 31, 2024. There were 77,452 shares issued as a result of options exercised during the nine months ended March 31, 2023.

XML

Revenue and Accounts Receivable

9 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue and Accounts Receivable

Note 5. – Revenue and Accounts Receivable

Revenues by payor were as follows for the three and nine months ended March 31, 2002 and 2023:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Medicare	$	3,207	$	3,521	$	11,021	$	10,377
Medicaid		1,506		1,802		4,898		5,048
Retail and Institutional Pharmacy		1,517		1,632		4,839		5,666
Managed Care & Other Insurance		1,022		1,032		3,179		4,572
Self-pay		189		180		532		564
Other		21		14		58		43
Total Net Revenues	$	7,462	$	8,181	$	24,527	$	26,270

The revenues for the three months ended March 31, 2024 includes $57 of prior period sales tax refunds as a result of a reduction in the accrued sales tax liability as described in Note 10. The revenues for nine months ended March 31, 2024 includes $437 of prior period sales tax refunds, compared to $2,615 increase in revenues in the nine months ended March 31, 2023 as a result of a reduction in the accrued sales tax liability as described in Note 10.

Accounts Receivable and Allowance for Doubtful Accounts

The Company adopted Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 326, Financial Statements – Credit Losses (“Topic 326”) with an adoption date of July 1, 2023. This standard requires a financial asset (or a group of financial assets) measured at amortized cost basis, to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial assets. The Company evaluates the valuation of accounts receivable concessions allowances based upon its historical collection trends, as well as its understanding of the nature and collectability of accounts based on their age and other

factors. The model is based on the credit losses expected to arise over the life of the asset based on the Company’s expectations as of the balance sheet date through analyzing historical customer data as well as taking into consideration current and estimated future economic trends. The Company adopted Topic 326 and determined it did not have a material financial impact.

The roll forward of the allowance for doubtful accounts for the three and nine months ended March 31, 2024 was as follows:

June 30, 2023 balance	$	532
Concession allowance expense		79
Write-offs		(203	)
September 30, 2023 balance		408
Concession allowance expense		67
Write-offs		(104	)
December 31, 2023 balance		371
Concession allowance expense		272
Write-offs		(363	)
March 31, 2024 balance	$	280

XML

Intangible Assets

9 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 6. – Intangible Assets

As of March 31, 2024 and June 30, 2023, intangible assets consist solely of an indefinite-lived trade name of $1,180 under the Pharmacy Segment.

Amortization expense was $0 and $6 for the three months ended March 31, 2024 and 2023, respectively. Amortization expense was $0 and $19 for the three months ended March 31, 2024 and 2023, respectively.

XML

Long-Term Debt

9 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Long-Term Debt

Note 7. – Long-Term Debt

Long-term debt of discontinued operations which is included in current liabilities held for sale consisted of the following:

	March 31, 2024		June 30, 2023
Finance Lease Obligations	$	0	$	14
Less current maturities		0		(14	)
Long-term Debt	$	0	$	0

XML

Income Taxes

9 Months Ended

Mar. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Note 8. – Income Taxes

Income tax benefit of $10 was recorded for continuing operations for the three months ended March 31, 2024. Income tax benefit of $6 (all state income benefit) was recorded for continuing operations for the three months ended March 31, 2023. Income tax benefit of $5 (all state income taxes) was recorded for continuing operations for the nine months ended March 31, 2024. Income tax benefit of $7 (all state income benefit) for continuing operations for the nine months ended March 31, 2023.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis

and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

At March 31, 2024, consistent with the above process, we evaluated the need for a valuation allowance against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $9,499 against the deferred tax asset so that there is no net long-term deferred income tax asset at March 31, 2024. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. A long-term deferred tax liability of $69 is recorded within other noncurrent liabilities in the accompanying condensed consolidated balance sheet of March 31, 2024 to reflect the deferred tax liability for the non-amortizing trade name intangible asset.

The principal negative evidence that led us to determine at March 31, 2024 that all the deferred tax assets should have full valuation allowances was historical tax losses and the projected current fiscal year tax loss. For purposes of evaluating our valuations allowances, the Company’s history of losses represent significant historical negative evidence and we have recognized none of our federal income tax net operating loss carry-forward of approximately $29,862.

For federal income tax purposes, at March 31, 2024, the Company had approximately $29,862 of estimated net operating loss carry-forwards available for use in future years subject to the possible limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal year 2023 through fiscal year 2038; however, with the enactment of the Tax Cut and Jobs Act on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. The Company’s returns for the periods prior to the fiscal year ended June 30, 2020 are no longer subject to potential federal and state income tax examination. Net operating loss carry-forwards generated in tax years prior to June 30, 2020 are still subject to redetermination in potential federal income tax examination.

XML

Leases

9 Months Ended

Mar. 31, 2024

Leases [Abstract]

Leases

Note 9. – Leases

The Company, as lessee, has operating leases relating to its pharmacy operations, certain medical equipment, and office equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, all of which are variable amounts based on actual costs. Variable lease costs also include escalating rent payments that are not fixed at commencement but are based on an index determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. Some leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rental rates. Leases may also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term. The components of lease cost and rent expense for the three and nine months ended March 31, 2024 and 2023 are as follows:

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
Lease Cost	March 31, 2024		March 31, 2023		March 31, 2024		March 31, 2023
Operating lease cost:
Operating lease cost	$	85	$	86	$	255	$	256
Short-term rent expense		7		5		19		18
Variable lease cost		0		1		1		2
Total operating lease cost	$	92	$	92	$	275	$	276

Supplemental balance sheet information relating to leases was as follows:

		As of		As of
		March 31,		June 30,
		2024		2023
Operating Leases:	Balance Sheet Classifications
Operating lease ROU Assets	ROU Assets	$	592	$	798
Current operating lease liabilities	Current operating lease liabilities		332		334
Long-term operating lease liabilities	Long-term operating lease liabilities	$	273	$	481

Supplemental cash flow and other information related to leases as of and for the three and nine months ended March 31, 2024 and 2023 are as follows:

	Three Months Ended						Nine Months Ended
Other information	March 31, 2024			March 31, 2023			March 31, 2024			March 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows of operating leases	$	85		$	86		$	255		$	256
Right-of-use assets obtained in exchange for new operating lease liabilities		0			0			18			16
Weighted-average remaining lease term:
Operating leases	1.82 years			2.74 years			1.82 years			2.74 years
Weighted-average discount rate:
Operating leases		0.98	%		1.02	%		0.98	%		1.02	%

Commitments relating to non-cancellable operating leases as of March 31, 2024 for each of the next five years and thereafter are as follows:

Payments due within	Operating Leases
1 year	$	337
2 years		252
3 years		15
4 years		10
5 years		0
Over 5 years		0
Total minimum future payments		614
Less: Imputed interest		(9	)
Total liabilities		605
Less: Current portion		(332	)
Long-term liabilities	$	273

XML

Sales Tax Payable

9 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

Sales Tax Payable

Note 10. – Sales Tax Payable

During the fiscal year ended June 30, 2019, the Pharmacy segment business amended its sales tax position with four different taxing authorities to avail its business of exemptions from state and local sales taxes in Louisiana on revenues from the sales of products and services to beneficiaries of government insurance programs to the extent reimbursed by the administrators of such programs. No such sales taxes for any period subsequent to June 30, 2019 have been paid on the related reimbursement received from the government insurance payers’ programs with respect to sales of such products and services. The Company has filed amended sales tax returns for periods still open under the applicable statutes of limitations claiming refunds of such sales taxes paid. Refunds have been received from three taxing authorities in the amounts claimed on amended returns and a settlement was reached with one taxing authority to offset future sales tax payable. Amounts claimed and received from two taxing authorities providing refunds were recorded as revenues in the fiscal year ended June 30, 2020 in the amount of $359. During the nine months ended March

31, 2024, the Company recorded a refund received of $321 as revenue for a sales tax refund which was received in October 2023 and during the three months and nine months ended March 31, 2024, the Company recorded $56 and $115, respectively, for prior period sales tax settlements.

In addition, until October 1, 2022, the Company accrued as payable amounts for sales tax estimates from these taxing authorities in amounts management believed would be payable if the Company's position did not prevail. During the nine months ended March 31, 2023, after discussions with the taxing authorities and external legal counsel, the Company determined that it was more likely than not that its position could be sustained going forward and accrued but unpaid sales tax would not be payable. Based on this determination, the Company reversed $2,615 of accrued sales tax during the nine months ended March 31, 2023 as an increase of net revenues

XML

Commitments and Contingencies

9 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. – Commitments and Contingencies

The Company has no contractual obligations, commitments and contingencies related to outstanding debt and interest (excluding operating leases, see Note 9) at March 31, 2024.

XML

Related Party Transactions

9 Months Ended

Mar. 31, 2024

Related Party Transactions [Abstract]

Related Party Transactions

Note 12. – Related Party Transactions

A director of the Company is senior counsel in a law firm which provides services to SunLink. The Company expensed an aggregate of $96 and $35 for legal services to this law firm in the three months ended March 31, 2024 and 2023, respectively and expensed an aggregate of $385 and $220 for legal services to this law firm in the nine months ended March 31, 2024 and 2023, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2024 and June 30, 2023 is outstanding legal expenses to this firm $154 and $36, respectively.

XML

Discontinued Operations (Tables)

9 Months Ended

Mar. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

Components of Pension Expense

The components of pension expense for the three and nine months ended March 31, 2024 and 2023, respectively, were as follows:

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Interest cost	$	10		$	13		$	32		$	39
Expected return on assets		(9	)		(11	)		(27	)		(32	)
Amortization of prior service cost		0			0			0			0
Net pension expense	$	1		$	2		$	5		$	7

Details of Statements of Operations from Discontinued Operations

Details of statements of operations from discontinued operations for the three and nine months ended March 31, 2024 and 2023, primarily reflecting the reporting of Trace as discontinued operations as a result of the Company's January 22, 2024 revised agreement to sell Trace and its plan to sell Trace Extended Care, are as follows:

	Three Months Ended							Nine Months Ended
	March 31,							March 31,
	2024				2023			2024			2023
Net Revenues	$	1,886			$	3,357		$	7,329		$	10,709
Costs and Expenses:
Salaries, wages and benefits		917				1,907			4,659			6,975
Supplies		146				237			702			910
Purchased services		280				748			1,587			2,324
Other operating expense		452				664			1,509			1,782
Rent and lease expense		8				45			75			105
Depreciation and amortization		42				98			308			297
Operating Profit (Loss)		41				(342	)		(1,511	)		(1,684	)
Other Income (Expense):
Losses on sale of assets		(613	)			0			(613	)		1
Federal stimulus - Provider relief funds		0				0			0			61
Interest income (expense), net		0				33			0			34
Loss from Discontinued Operations before income taxes		(572	)	—		(309	)		(2,124	)		(1,588	)
Impairment loss of Trace Assets and related sale expenses before income taxes		0				0			(2,032	)		0
Loss from Discontinued Operations before income taxes		(572	)			(309	)		(4,156	)		(1,588	)
Income Tax Expense		0				0			0			0
Loss from Discontinued Operations, net of tax	$	(572	)		$	(309	)	$	(4,156	)	$	(1,588	)

Details of assets and liabilities held for sale

Details of assets and liabilities held for sale at March 31, 2024 and June 30, 2023, which primarily reflect the Trace Extended Care's assets to be sold and liabilities to be assumed as a result of the Company's January 22, 2024 revised agreement to sell the Trace hospital assets and its plans to dispose of Trace Extended Care are as follows:

	March 31,			June 30,
	2024			2023
Receivables - net	$	667		$	1,659
Inventory		2			125
Prepaid expense and other assets		7			136
Property, plant and equipment, net		4,529			5,564
Impairment reserve		(1,695	)		0
Right of use assets		0			246
Noncurrent assets		2			2
Total assets held for sale	$	3,512		$	7,732
Accounts payable	$	418		$	783
Accrued payroll and related taxes		91			361
Current operating lease liabilities		0			61
Other accrued expenses		54			121
Long-term operating lease liabilities		0			192
Total liabilities held for sale	$	563		$	1,518

XML

Revenue and Accounts Receivable (Tables)

9 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Summary of Revenues by Payor

Revenues by payor were as follows for the three and nine months ended March 31, 2002 and 2023:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2024		2023		2024		2023
Medicare	$	3,207	$	3,521	$	11,021	$	10,377
Medicaid		1,506		1,802		4,898		5,048
Retail and Institutional Pharmacy		1,517		1,632		4,839		5,666
Managed Care & Other Insurance		1,022		1,032		3,179		4,572
Self-pay		189		180		532		564
Other		21		14		58		43
Total Net Revenues	$	7,462	$	8,181	$	24,527	$	26,270

Summary of Allowance For Doubtful Accounts

The roll forward of the allowance for doubtful accounts for the three and nine months ended March 31, 2024 was as follows:

June 30, 2023 balance	$	532
Concession allowance expense		79
Write-offs		(203	)
September 30, 2023 balance		408
Concession allowance expense		67
Write-offs		(104	)
December 31, 2023 balance		371
Concession allowance expense		272
Write-offs		(363	)
March 31, 2024 balance	$	280

XML

Long-Term Debt (Tables)

9 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Summary of Long Term Debt of Discontinued Operations

Long-term debt of discontinued operations which is included in current liabilities held for sale consisted of the following:

	March 31, 2024		June 30, 2023
Finance Lease Obligations	$	0	$	14
Less current maturities		0		(14	)
Long-term Debt	$	0	$	0

XML

Leases (Tables)

9 Months Ended

Mar. 31, 2024

Leases [Abstract]

Summary of Components of Lease Cost and Rent Expense

The components of lease cost and rent expense for the three and nine months ended March 31, 2024 and 2023 are as follows:

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
Lease Cost	March 31, 2024		March 31, 2023		March 31, 2024		March 31, 2023
Operating lease cost:
Operating lease cost	$	85	$	86	$	255	$	256
Short-term rent expense		7		5		19		18
Variable lease cost		0		1		1		2
Total operating lease cost	$	92	$	92	$	275	$	276

Summary of Supplemental Balance Sheet Information

Supplemental balance sheet information relating to leases was as follows:

		As of		As of
		March 31,		June 30,
		2024		2023
Operating Leases:	Balance Sheet Classifications
Operating lease ROU Assets	ROU Assets	$	592	$	798
Current operating lease liabilities	Current operating lease liabilities		332		334
Long-term operating lease liabilities	Long-term operating lease liabilities	$	273	$	481

Summary of Supplemental Cash Flow and Other Information Related to Leases

Supplemental cash flow and other information related to leases as of and for the three and nine months ended March 31, 2024 and 2023 are as follows:

	Three Months Ended						Nine Months Ended
Other information	March 31, 2024			March 31, 2023			March 31, 2024			March 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows of operating leases	$	85		$	86		$	255		$	256
Right-of-use assets obtained in exchange for new operating lease liabilities		0			0			18			16
Weighted-average remaining lease term:
Operating leases	1.82 years			2.74 years			1.82 years			2.74 years
Weighted-average discount rate:
Operating leases		0.98	%		1.02	%		0.98	%		1.02	%

Summary of Non-cancellable Operating and Finance Leases

Commitments relating to non-cancellable operating leases as of March 31, 2024 for each of the next five years and thereafter are as follows:

Payments due within	Operating Leases
1 year	$	337
2 years		252
3 years		15
4 years		10
5 years		0
Over 5 years		0
Total minimum future payments		614
Less: Imputed interest		(9	)
Total liabilities		605
Less: Current portion		(332	)
Long-term liabilities	$	273

XML

Business Operations - Additional Information (Detail)	Aug. 02, 2023 shares
Series C Preferred Share [Member]
Business And Organization [Line Items]
Series C preferred share voting rights	Each of the 7,032 Series C Preferred Shares issued was entitled to one million (1,000,000) votes and each Series C Fractional Interest in a Series C Preferred Share was entitled to one thousand (1,000) votes out of such one million votes.
Preferred stock shares issued	7,032
Common Share [Member]
Business And Organization [Line Items]
Common shares voting rights	Each Common Share was entitled to one (1) vote as a Common Share and also one thousand (1,000) votes for the corresponding Series C Fractional Interest thereon, on each matter properly brought before a special shareholders’ meeting which was held on October 19, 2023 and at which the Corporation was reincorporated from the state of Ohio to Georgia (the “Special Meeting”).

XML

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Interest Cost	$ 10	$ 13	$ 32	$ 39
Expected return on assets	(9)	(11)	(27)	(32)
Amortization of prior service cost	0	0	0	0
Net pension expense	$ 1	$ 2	$ 5	$ 7

XML

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended			6 Months Ended	9 Months Ended
	Jul. 31, 2024	Jan. 22, 2024	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transaction Expenses				$ 58
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment reserve			$ (1,695)				$ (1,695)		$ 0
Contribution to pension plan							15
Expected contribution to pension plan during the remaining fiscal year			5				5
Losses on sale of assets			(613)		$ 0		(613)	$ 1
Sale of Trace Regional Health Systems. Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale Of Personal And Intangible Assets		$ 500
Lease Term		6 months
Net Lease of Certain Hospital Real Property (Per Month)		$ 20
Impairment Loss						$ 1,974
Impairment reserve			1,695				$ 1,695
Transaction Expenses			55
Losses on sale of assets			$ (613)
Sale of Trace Regional Health Systems. Inc [Member] | Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase certain real estate of Trace	$ 2,000

XML

Discontinued Operations - Details of statements of operations from discontinued operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net revenues	$ 7,462	$ 8,181	$ 24,527	$ 26,270
Costs and Expenses [Abstract]
Salaries, wages and benefits	2,652	2,543	7,937	7,547
Supplies	36	39	109	104
Other operating expenses	589	601	2,279	1,854
Rent and lease expense	92	92	275	276
Depreciation and amortization	342	316	960	873
Operating Profit (Loss)	(853)	(467)	(1,736)	1,186
Other Income (Expense):
Interest income (expense), net	19	8	70	13
Earnings (Loss) from Continuing Operations before income taxes	(834)	(459)	(1,664)	1,212
Income Tax Benefit	(10)	(6)	(5)	(7)
Loss from Discontinued Operations, net of tax	(572)	(309)	(4,156)	(1,588)
Life Sciences And Engineering Segment [Member]
Net revenues	1,886	3,357	7,329	10,709
Costs and Expenses [Abstract]
Salaries, wages and benefits	917	1,907	4,659	6,975
Supplies	146	237	702	910
Purchased services	280	748	1,587	2,324
Other operating expenses	452	664	1,509	1,782
Rent and lease expense	8	45	75	105
Depreciation and amortization	42	98	308	297
Operating Profit (Loss)	41	(342)	(1,511)	(1,684)
Other Income (Expense):
Losses on sale of assets	(613)	0	(613)	1
Federal Stimulus Provider Relief Funds	0	0	0	61
Interest income (expense), net	0	33	0	34
Loss from Discontinued Operations before income taxes	(572)	(309)	(2,124)	(1,588)
Impairment loss of Trace Assets and related sale expenses before income taxes	0	0	(2,032)	0
Earnings (Loss) from Continuing Operations before income taxes	(572)	(309)	(4,156)	(1,588)
Income Tax Benefit	0	0	0	0
Loss from Discontinued Operations, net of tax	$ (572)	$ (309)	$ (4,156)	$ (1,588)

XML

Discontinued Operations - Summary of Assets and Liabilities Held for Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current operating lease liabilities	$ 332	$ 334
Long-term operating lease liabilities	0	0
Life Sciences And Engineering Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Receivables - net	667	1,659
Inventory	2	125
Prepaid expense and other assets	7	136
Property, plant and equipment, net	4,529	5,564
Impairment reserve	(1,695)	0
Right of use assets	0	246
Noncurrent assets	2	2
Total assets held for sale	3,512	7,732
Accounts payable	418	783
Accrued payroll and related taxes	91	361
Current operating lease liabilities	0	61
Other accrued expenses	54	121
Long-term operating lease liabilities	0	192
Total liabilities held for sale	$ 563	$ 1,518

XML

Shareholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation, amount recognized	$ 0	$ 0	$ 0	$ 0
Options exercised			9,000	77,452

XML

Revenue and Accounts Receivable - Summary of Revenue by Payor (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	$ 7,462	$ 8,181	$ 24,527	$ 26,270
Medicare [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	3,207	3,521	11,021	10,377
Medicaid [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	1,506	1,802	4,898	5,048
Retail and Institutional Pharmacy [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	1,517	1,632	4,839	5,666
Managed Care & Other Insurance [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	1,022	1,032	3,179	4,572
Self-Pay [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	189	180	532	564
Other [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net revenues	$ 21	$ 14	$ 58	$ 43

XML

Revenue and Accounts Receivable - Summary of Allowance For Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Beginning, balance	$ 371	$ 408	$ 532
Concession allowance expense	272	67	79
Write-offs	(363)	(104)	(203)
Ending, balance	$ 280	$ 371	$ 408

XML

Revenue and Accounts Receivable - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Increase in revenue			$ 2,615
Reversed Accrued Sales Tax	$ 57	$ 437

XML

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0	$ 6	$ 0	$ 19
Intangible assets	$ 1,180		$ 1,180		$ 1,180

XML

Long-Term Debt - Summary of Long-Term Debt of Discontinued Operations (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Debt Disclosure [Abstract]
Finance Lease Obligations	$ 0	$ 14
Less current maturities	0	(14)
Long-term Debt	$ 0	$ 0

XML

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 10	$ 6	$ 5	$ 7
Deferred income tax valuation allowance	9,499		9,499
Net long-term deferred income tax asset or liability	0		0
Long-term deferred tax liability	69		69
Net operating loss carry-forward	$ 29,862		$ 29,862
Net operating loss carryforward expiration year	2023 through fiscal year 2038

XML

Lease - Summary of Components of Lease Cost and Rent Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Operating lease cost:
Operating lease cost	$ 85	$ 86	$ 255	$ 256
Short-term rent expense	7	5	19	18
Variable lease cost	0	1	1	2
Total operating lease cost	$ 92	$ 92	$ 275	$ 276

XML

Lease - Summary of Supplemental Balance Sheet Information Relating to Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Operating Leases:
Operating lease ROU Assets	$ 592	$ 798
Current operating lease liabilities	332	334
Long-term operating lease liabilities	$ 273	$ 481

XML

Lease - Summary of Supplemental Cash Flow and Other Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows of operating leases	$ 85	$ 86	$ 255	$ 256
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 0	$ 0	$ 18	$ 16
Weighted-average remaining lease term:
Operating leases	1 year 9 months 25 days	2 years 8 months 26 days	1 year 9 months 25 days	2 years 8 months 26 days
Weighted-average discount rate:
Operating leases	0.98%	1.02%	0.98%	1.02%

XML

Lease - Summary of Non-cancellable Operating and Finance Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Leases [Abstract]
1 year	$ 337
2 years	252
3 years	15
4 years	10
5 years	0
Over 5 years	0
Total minimum future payments	614
Less: Imputed interest	(9)
Total liabilities	605
Less: Current portion	(332)	$ (334)
Long-term operating lease liabilities	$ 273	$ 481

XML

Sales Tax Payable - Additional Information (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2024 USD ($) Authority	Mar. 31, 2023 USD ($)	Jun. 30, 2020 USD ($)
Payables and Accruals [Abstract]
Number of taxing authorities | Authority		3
Amounts claimed and received				$ 359
Sales Tax Receivable		$ 321
Sales tax settlement	$ 56	$ 115
Accrued sales tax			$ 2,615

XML

Related Party Transactions - Additional Information (Detail) - Management [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Related Party Transaction [Line Items]
Legal services to these law firms	$ 96	$ 35	$ 385	$ 220
Amount payable to law firms	$ 154		$ 154		$ 36